Initializing potency table...
Ligand source activities (1 row/activity)
Ligands | Receptor | Activity | Chemical information | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Common name | GPCRdb ID | Reference ligand | Vendors | Species | Assay Type | Activity Type | Activity Relation | Activity Value | p-value (-log) | Fold selectivity | Tested GPCRs | Assay Description | Source | Mol weight | Rot Bonds | H don | H acc | LogP | Smiles | DOI | |
Ligands | Receptor | Activity | Chemical information | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Common name | GPCRdb ID | Reference ligand | Vendors | Species | Assay Type | Activity Type | Activity Relation | Activity Value | p-value (-log) | Fold selectivity | Tested GPCRs | Assay Description | Source | Mol weight | Rot Bonds | H don | H acc | LogP | Smiles | DOI | |
A-71623 | 207 | None | 26 | Human | Binding | IC50 | = | 1900.00 | 5.72 | - | 3 | Inhibitory activity against cholecystokinin type A receptor from bovine striatal binding assay | ChEMBL | - | - | - | - | - | - | https://dx.doi.org/10.1021/jm00100a033 | |
A-71623 | 207 | None | 26 | Rat | Binding | Ki | = | 0.30 | 9.52 | 831 | 3 | Inhibition of [125I]BH-CCK-8 binding to Cholecystokinin type A receptor of rat pancreatic tissue | ChEMBL | - | - | - | - | - | - | https://dx.doi.org/10.1021/jm990252e | |
A-71623 | 207 | None | 26 | Rat | Binding | IC50 | = | 0.05 | 10.30 | 831 | 3 | Inhibitory activity against cholecystokinin type A receptor from rat pancreas binding assay | ChEMBL | - | - | - | - | - | - | https://dx.doi.org/10.1021/jm00100a033 | |
AFATINIB | 11001 | None | 62 | Human | Binding | AC50 | = | 10999.90 | 4.96 | - | 4 | Binding affinity towards human CCKAR in an in vitro assay with cellular components measured by scintillation proximity assay | ChEMBL | 485.2 | 8 | 2 | 7 | 4.39 | CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1 | https://dx.doi.org/10.1038/s41467-023-40064-9 | |
ALPRAZOLAM | 205943 | None | 20 | Rat | Binding | IC50 | = | 64000.00 | 4.19 | - | 6 | Displacement of [125I]CCK from Cholecystokinin receptor of rat pancreas | ChEMBL | 308.1 | 1 | 0 | 4 | 3.58 | Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2 | https://dx.doi.org/10.1021/jm00396a028 | |
ALPRAZOLAM | 205943 | None | 20 | Rat | Binding | pIC50 | = | 4.19 | 8.38 | - | 6 | Displacement of [125I]CCK from Cholecystokinin receptor of rat pancreas | Drug Central | 308.1 | 1 | 0 | 4 | 3.58 | Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2 | - | |
AMIGLUMIDE | 9901 | None | 8 | Guinea pig | Binding | IC50 | = | 4200.00 | 5.38 | - | 1 | Compound was evaluated for the binding affinity against Cholecystokinin type A receptor in cortical cells. | ChEMBL | 440.3 | 14 | 2 | 3 | 5.01 | CCCCCN(CCCCC)C(=O)[C@@H](CCC(=O)O)NC(=O)c1ccc2ccccc2c1 | https://dx.doi.org/10.1021/jm00124a003 | |
AMIGLUMIDE | 9901 | None | 8 | Guinea pig | Binding | IC50 | = | 12.00 | 7.92 | - | 1 | Compound was evaluated for the binding affinity against Cholecystokinin type A receptor in pancreatic acinar cell | ChEMBL | 440.3 | 14 | 2 | 3 | 5.01 | CCCCCN(CCCCC)C(=O)[C@@H](CCC(=O)O)NC(=O)c1ccc2ccccc2c1 | https://dx.doi.org/10.1021/jm00124a003 | |
AMIGLUMIDE | 9901 | None | 8 | Guinea pig | Binding | IC50 | = | 12.00 | 7.92 | - | 1 | Inhibition of [125I]Bolton-Hunter CCK-8 binding to cholecystokinin type A receptor in guinea pig pancreatic membranes. | ChEMBL | 440.3 | 14 | 2 | 3 | 5.01 | CCCCCN(CCCCC)C(=O)[C@@H](CCC(=O)O)NC(=O)c1ccc2ccccc2c1 | https://dx.doi.org/10.1021/jm00116a002 | |
AMSACRINE | 167616 | None | 49 | Human | Binding | AC50 | = | 21999.90 | 4.66 | - | 15 | Binding affinity towards human CCKAR in an in vitro assay with cellular components measured by scintillation proximity assay | ChEMBL | 393.1 | 5 | 2 | 5 | 4.51 | COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12 | https://dx.doi.org/10.1038/s41467-023-40064-9 | |
ARL-15849 | 472 | None | 0 | Rat | Binding | pKi | None | - | 10.50 | 7943 | 2 | Unclassified | Guide to Pharmacology | - | - | - | - | - | - | https://pubmed.ncbi.nlm.nih.gov/9476993 | |
ASPERLICIN | 99522 | None | 8 | Human | Binding | IC50 | = | 1400.00 | 5.85 | - | 1 | Inhibition of cholecystokinin A receptor | ChEMBL | 535.2 | 4 | 3 | 7 | 3.14 | CC(C)C[C@@H]1N[C@H]2N(C1=O)c1ccccc1[C@@]2(O)C[C@@H]1NC(=O)c2ccccc2-n2c1nc1ccccc1c2=O | https://dx.doi.org/10.1021/np9800102 | |
ATAZANAVIR | 10423 | None | 49 | Human | Binding | AC50 | = | 17599.90 | 4.75 | - | 4 | Binding affinity towards human CCKAR in an in vitro assay with cellular components measured by scintillation proximity assay | ChEMBL | 704.4 | 14 | 5 | 9 | 4.21 | COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C | https://dx.doi.org/10.1038/s41467-023-40064-9 | |
BEPRIDIL | 4301 | None | 35 | Human | Binding | AC50 | = | 23230.00 | 4.63 | - | 22 | Binding affinity towards human CCKAR in an in vitro assay with cellular components measured by scintillation proximity assay | ChEMBL | 366.3 | 10 | 0 | 3 | 4.83 | CC(C)COCC(CN(Cc1ccccc1)c1ccccc1)N1CCCC1 | https://dx.doi.org/10.1038/s41467-023-40064-9 | |
CANDESARTAN CILEXETIL | 4402 | None | 68 | Human | Binding | AC50 | = | 21999.90 | 4.66 | - | 29 | Binding affinity towards human CCKAR in an in vitro assay with cellular components measured by scintillation proximity assay | ChEMBL | 610.3 | 10 | 1 | 11 | 6.32 | CCOc1nc2cccc(C(=O)OC(C)OC(=O)OC3CCCCC3)c2n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1 | https://dx.doi.org/10.1038/s41467-023-40064-9 | |
cannabidiol | 788 | None | 26 | Human | Binding | AC50 | = | 18330.30 | 4.74 | - | 23 | Binding affinity towards human CCKAR in an in vitro assay with cellular components measured by scintillation proximity assay | ChEMBL | 314.2 | 6 | 2 | 2 | 5.85 | C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O | https://dx.doi.org/10.1038/s41467-023-40064-9 | |
CCK-33 | 815 | None | 0 | Rat | Binding | pKd | = | - | 9.30 | 3 | 4 | Unclassified | Guide to Pharmacology | - | - | - | - | - | - | https://pubmed.ncbi.nlm.nih.gov/6256771 | |
CCK-8 | 822 | None | 42 | Human | Binding | IC50 | = | 1.32 | 8.88 | -2 | 6 | In vitro for binding affinity against human cholecystokinin type A receptor. | ChEMBL | - | - | - | - | - | - | https://dx.doi.org/10.1021/jm970265x | |
CCK-8 | 822 | None | 42 | Human | Binding | pKi | = | 9.55 | 8.02 | -2 | 6 | Displacement of radiolabeled CCK-8s from human CCK1 receptor | Drug Central | - | - | - | - | - | - | - | |
CCK-8 | 822 | None | 42 | Human | Binding | IC50 | = | 0.63 | 9.20 | -2 | 6 | Compound was tested in vitro for its ability to displace [125I]Bolton-Hunter CCK-8 from membrane preparation isolated from CHO-KI cells stably transfected with cDNA of human Cholecystokinin type A receptor | ChEMBL | - | - | - | - | - | - | https://dx.doi.org/10.1021/jm9601664 |
Showing 1 to 20 of 2,759 entries
Ligands | Receptor | Activity | Chemical information | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Common name |
GPCRdb ID |
Reference ligand |
Vendors | Species | Assay Type |
Activity Type |
Activity Relation |
Activity Value |
p-value (-log) |
Fold selectivity |
Tested GPCRs |
Assay Description |
Source | Mol weight |
Rot Bonds |
H don | H acc | LogP | Smiles | DOI | |